New treatment targets for ENKTL.
| Target | Treatment | Patients | Outcome | Reference |
|---|---|---|---|---|
| PD-1/PD-L1 | Pembrolizumab | 7 relapsed | 5 CR, 2 PR | [69] |
| Nivolumab | 3 relapsed | 3 CR | [71] | |
| CD38 | Daratumumab | 2 RR | 1 CR, 1 PR | [74, 75] |
| CD30 | BV | 2 refractory | 2 CR | [79, 80] |
| CCR4 | Mogamulizumab | Preclinical | NA | [85] |
| LMP1/LMP2 | Autologous CTLs | 11 ENKTL6 active disease5 in CR | 9 CR 4 CR 5 remained CR | [86] |
| Autologous CTLs | 10 ENKTL in CR | 9 remained CR | [87] | |
| JAK/STAT | Vorinostat | 1 pediatric ENKTL | CR | [89] |
| Ruxolitinib | Clinical trial | Ongoing | [NCT02974647] |
Abbreviations: BV, brentuximab vedotin; CR, complete remission; CTL, cytotoxic T lymphocyte; ENKTL, extranodal NK/T cell lymphoma; PR, partial remission; RR, refractory/relapsed.
Blood Res 2020;55:S63~S71 https://doi.org/10.5045/br.2020.S011
© Blood Research
© 2024. BLOOD RESEARCH All rights reserved. Powered by INFOrang Co., Ltd